Search Results

Displaying Results 1-3 of 3 "'CYT'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign

Sep 09, 2026, 12:38 ET Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign

The financing is expected to support continued development of CYT-108, Cytonics' investigational engineered alpha-2-macroglobulin, or A2M, biologic. CYT-108 is designed to inhibit multiple classes of destructive proteases involved in cartilage degradation. The

More news about: Cytonics Corporation

Cytonics Completes First-In-Human Phase 1 Clinical Study Report for <em>CYT-108,</em> Advancing Program Toward Next Phase of Development.

Jun 30, 2026, 06:30 ET Cytonics Completes First-In-Human Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development.

regulatory strategy and Phase 1b/2a clinical planning activities as the company continues development of CYT-108 as a potential disease-modifying therapy for osteoarthritis.About CYT-108CYT-108 is a recombinant variant of the endogenous alpha-2-macroglobulin (A2M) blood serum protein. The

More news about: Cytonics Corporation

Oct 07, 2025, 18:00 ET Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer

first-in-human Phase I clinical trial of CYT-101. CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy for the treatment of glioblastoma multiforme (GBM) and other

More news about: Cyteph Pty Ltd

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.